Safety, tolerability, pharmacokinetics, and antitumour activity of oleclumab in Japanese patients with advanced solid malignancies: a phase I, open-label study Shunsuke KondoSatoru IwasaNoboru Yamamoto Original Article Open access 07 November 2022 Pages: 1795 - 1804
First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048 Shunji TakahashiNobuhiko OridateMakato Tahara Original Article Open access 20 October 2022 Pages: 1805 - 1817
Tumor–stroma ratio can predict lymph-node metastasis in cT1/2N0 oral tongue squamous cell carcinoma independent of tumor budding grade Toshihiko SakaiYuki SaitoTatsuya Yamasoba Original Article 05 October 2022 Pages: 1818 - 1827
Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study Shunichi SugawaraMasashi KondoYuichiro Ohe Original Article Open access 29 August 2022 Pages: 1828 - 1838
Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study Shunichi SugawaraMasashi KondoYuichiro Ohe Correction Open access 16 October 2022 Pages: 1839 - 1840
Phase I/II study of nedaplatin and nab-paclitaxel for patients with previously untreated advanced squamous cell lung cancer: Kanto Respiratory Disease Study Group (KRSG) 1302 Takashi KasaiKiyoshi MoriMitsuo Nakayama Original Article 14 October 2022 Pages: 1841 - 1848
Combining nutritional status with TNM stage: a physiological update on gastric cancer staging for improving prognostic accuracy in elderly patients Kotaro SugawaraHiroharu YamashitaYasuyuki Seto Original Article 18 October 2022 Pages: 1849 - 1858
Biweekly TAS-102 and bevacizumab as third-line chemotherapy for advanced or recurrent colorectal cancer: a phase II, multicenter, clinical trial (TAS-CC4 study) Hiroshi MatsuokaTakeshi Yamadathe TAS CC4 Study Group Original Article 06 October 2022 Pages: 1859 - 1866
Characterizing cyclin-dependent kinase 12(CDK12)-altered aggressive prostate cancer: a twelve-case series Tomohiro IwasawaTakeo KosakaMototsugu Oya Original Article Open access 21 October 2022 Pages: 1867 - 1873
Comparison of treatment outcomes between first-line chemotherapy with or without bevacizumab for advanced ovarian, fallopian tube, and primary peritoneal cancer (Tohoku gynecologic cancer unit: TGCU-RS001 study) Tadahiro ShojiEriko TakatoriYoshihito Yokoyama Original Article 10 October 2022 Pages: 1874 - 1880
A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors Susana CamposUrsula MatulonisRichard Penson Original Article 08 November 2022 Pages: 1881 - 1890
Long non-coding RNA NR2F2-AS1 regulates human osteosarcoma growth and metastasis through miR-425-5p-mediated HMGB2 Jia YeHui HeZhihui Jin Original Article 21 October 2022 Pages: 1891 - 1903
Functional outcomes at PICU discharge in hemato-oncology children at a tertiary oncology center in Hong Kong Karen K. Y. LeungSamiran RayKam Lun Hon Original Article 23 September 2022 Pages: 1904 - 1915
